atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Exceptional clinical leadership in the 21st century demands strong communication skills and the ability to listen to colleagues. Effective leadership necessitates a cultural shift within organisations, fostering openness and innovation.
Catch up on insightful discussions from the expert panel featuring…
Congratulations on the launch of "Every Dose Used-Reducing Wasted Medicines Playbook" co-authored by Deloitte & @YewMaker on behalf of the Sustainable Medicines Partnership. Download the report here.